Development Programs

Web-pic-1

Groundbreaking Cannabinoid-based Medicines

Innovative medicines targeting unmet needs, backed by real-world data.

Emyria’s proprietary, ultra-pure cannabinoid treatments have been formulated to address multiple, large unmet needs like psychological distress, irritable bowel syndrome and more - all backed by our unique Real World Data (RWD) model.

Next-generation MDMA Analogue Program

Developing innovative treatments for severe psychological conditions

Emyria has exclusive access to a world-class library of over 100 MDMA analogues developed over 10 years by Dr. Matt Piggott at the University of Western Australia (UWA).

MDMA analogues have unique biochemical properties that make them attractive small molecules to develop into registered treatments for severe psychological conditions such as Post-Traumatic Stress Disorder.

UWA’s library is therefore a highly valuable drug discovery resource.

Web-pic-2
Web-pic-3

Research & Data Programs

Robust and ethically-sourced real-world patient data and technology-driven research programs

Our unique data platform helps us manage, monitor and improve the safety and efficacy of novel treatments for patients with unmet medical needs.

Emyria is also leading numerous innovative grant and award-winning research programs with global partners involving remote monitoring technology and psychedelic-assisted therapy.

Call 1300 436 363Contact